2-(2-Amino-propyl)-phenol | 87835-14-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-Amino-propyl)-phenol
• 英文别名: 2-(2-Aminopropyl)phenol
• CAS: 87835-14-1
• 化学式: C₉H₁₃NO
• mdl: MFCD01707829
• 分子量: 151.208
• InChiKey: BCYNCBWCTHFJIU-UHFFFAOYSA-N

物化性质

• 沸点：
  265.4±15.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

ADMET

代谢

2-(2-氨基丙基)苯酚是已知的人类代谢物，来源于(2r)-1-(2-甲氧基苯基)丙烷-2-胺。

2-(2-Aminopropyl)phenol is a known human metabolite of (2r)-1-(2-methoxyphenyl)propan-2-amine.

来源:NORMAN Suspect List Exchange

反应信息

• 作为产物：
  描述：

  3-(2-methoxyphenyl)-2-methylacrylic acid 在 盐酸 、 氢氧化钾 、 ammonium hydroxide 、 sodium hydroxide 、 氯化亚砜 、 氯仿 、 溴 、 溶剂黄146 、 铂 作用下， 生成 2-(2-Amino-propyl)-phenol
  参考文献：
  名称：

  Physiologically Active Phenethylamines. I. Hydroxy- and Methoxy-α-methyl-β-Phenethylamines (β-Phenylisopropylamines)

  摘要：

  DOI：

  10.1021/ja01269a065

文献信息

• Novel aminotransferase, gene encoding the same, and method of using them
  申请人：Ito Noriyuki

  公开号：US20100285544A1

  公开（公告）日：2010-11-11

  The invention relates to a novel aminotransferase, DNA encoding the enzyme, a recombinant vector into which the DNA has been introduced, and a transformant into which the vector has been introduced. Further, the invention also relates to a method for producing an optically active amino compound utilizing the enzyme or transformant. The aminotransferase of the invention has an ability of efficiently converting a ketone compound, particularly a cyclic ketone compound to an optically active amino compound. According to the invention, a method for efficiently producing an optically active amino compound, particularly an optically active cyclic amino compound is provided.

  本发明涉及一种新型氨基转移酶、编码该酶的DNA、已引入该DNA的重组载体以及已引入该载体的转化菌株。此外，本发明还涉及一种利用该酶或转化菌株生产光学活性氨基化合物的方法。本发明的氨基转移酶能够高效地将酮类化合物，尤其是环状酮类化合物转化为光学活性氨基化合物。根据本发明，提供了一种高效生产光学活性氨基化合物，尤其是光学活性环状氨基化合物的方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM
  申请人：ITO NORIYUKI

  公开号：US20120164724A1

  公开（公告）日：2012-06-28

  The invention relates to a novel aminotransferase, DNA encoding the enzyme, a recombinant vector into which the DNA has been introduced, and a transformant into which the vector has been introduced. Further, the invention also relates to a method for producing an optically active amino compound utilizing the enzyme or transformant. The aminotransferase of the invention has an ability of efficiently converting a ketone compound, particularly a cyclic ketone compound to an optically active amino compound. According to the invention, a method for efficiently producing an optically active amino compound, particularly an optically active cyclic amino compound is provided.

  本发明涉及一种新型氨基转移酶、编码该酶的DNA、将该DNA引入的重组载体以及将该载体引入的转化体。此外，本发明还涉及利用该酶或转化体生产光学活性氨基化合物的方法。本发明中的氨基转移酶能够有效地将酮化合物，特别是环状酮化合物转化为光学活性氨基化合物。根据本发明，提供了一种有效生产光学活性氨基化合物，特别是光学活性环状氨基化合物的方法。
• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。
• Stable plurilamellar vesicles
  申请人：THE LIPOSOME COMPANY, INC.

  公开号：EP0092453A2

  公开（公告）日：1983-10-26

  A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.

  本文介绍了一种新型的、经过重大改进的脂质囊泡--稳定多核酰胺囊泡（SPLVs）及其制造工艺。SPLV 在储存过程中非常稳定，可用于体内化合物的持续释放和疾病治疗。